YongZhang

Beijing Protgen Biotechnology Development Co., Ltd. (Protgen) is a leading Chinese biopharmaceutical company specializing in the research, development, and large-scale production of recombinant protein drugs and in vitro diagnostic (IVD) reagents. Founded in 2004 by Professor Luo Yongzhang of Tsinghua University, the company serves as a key industrialization unit for the National Engineering Research Center for Protein Technology. Protgen is globally recognized for developing the first quantitative detection kit for Heat Shock Protein 90 alpha (Hsp90α), a pan-cancer biomarker approved in China for monitoring lung and liver cancers. Its therapeutic pipeline includes recombinant human serum albumin for metabolic diseases and anti-aging, as well as engineered endostatin variants for oncology. The company maintains a robust intellectual property portfolio with over 80 authorized patents and operates multiple specialized branches across China.